

July 17, 2026

News Release

Company: Olympus Corporation

Bob White, Director, Representative Executive Officer, President and CEO

(Code: 7733, Prime, Tokyo Stock Exchange)

Contact: Takaaki Sakurai, Vice President, Investor Relations

TEL: +81-42-642-2111

Notice Concerning Change of Executive Officer

Olympus Corporation ("Olympus") hereby announces that the Board of Directors resolved today to change the Executive Officer and Chief Quality Officer, effective August 1, as described below.

1. Reason for change of Executive Officer

Boris Shkolnik led the establishment of the global quality function and system as Olympus, strengthened its position as a global medtech company. During this transformation, he enhanced engagement with the FDA, advanced the Quality Management System to improve global standardization and audit readiness, designed and established global Quality and Regulatory Affairs functions and drove the adoption of a patient safety and quality culture across the organization. His leadership helped establish a stronger foundation for quality and regulatory compliance.

To support our strategic growth investments, we remain committed to proactive and constructive engagement with global regulators, including the US FDA, with a clear focus on achieving a sustainable, fully compliant end state that underpins long-term value creation.

Brian Barry will succeed him and lead the next phase of the company's quality transformation; he brings more than 40 years of leadership experience across global Quality, Regulatory Affairs, Medical Safety, and Clinical Affairs. He has demonstrated expertise in strategic planning, organizational development, regulatory compliance, lean transformation, and regulatory agency engagement. With a strong track record in leading complex acquisitions and divestitures, improving quality system performance, and successfully resolving regulatory challenges, Brian will play a key role in further strengthening our quality system, advancing patient safety and driving a quality culture.

2. Names and job titles of newly appointed and retiring executive officers

(1) Newly appointed executive officer

Name	Current job titles	New job titles after August 1, 2026
Brian Barry	—	Executive Officer and Chief Quality Officer

(2) Departing executive officer

Name	Current job titles
Boris Shkolnik	Executive Officer and Chief Quality Officer

3. Career summary of newly appointed executive officer

Brian Barry

Date of Birth:	August 22, 1959	
Career summary:	July 1981	Joined United States Surgical Corporation
	September 1988	Quality Assurance Manager, Disposable Products, Corometrics Medical Systems, Inc. (acquired by Marquette Electronics)
	December 1989	Sr. Director, Regulatory Affairs & Quality Assurance, Corometrics Medical Systems, Inc. (acquired by Marquette Electronics)
	July 1994	Vice President, Regulatory Affairs & Quality Assurance, Bard Access Systems, Inc.
	January 1997	Vice President, Corporate Regulatory Affairs, C. R. Bard, Inc.
	December 2000	Vice President, Regulatory, Clinical & Quality Affairs, Medtronic Xomed, Inc.
	September 2003	Vice President, Corporate Regulatory Affairs & Clinical Affairs, C. R. Bard, Inc.
	June 2007	Vice President, Quality, Regulatory, Clinical & Medical Affairs, Medtronic Sofamor Danek USA, Inc.
	September 2013	Vice President, Corporate Regulatory Affairs, Covidien plc (acquired by Medtronic plc)
	February 2015	Group Vice President, Quality, Regulatory Affairs, Medical Safety & Scientific Communications, Minimally Invasive Therapies Group, Medtronic plc
	February 2021	Vice President, Global Regulatory Shared Services, Medtronic Corporate Regulatory Affairs, Medtronic plc
	January 2023	Vice President, Medtronic Clinical & Regulatory Solutions, Medtronic plc (present) (Note 1)
	August 2026	Join Olympus Corporation of the Americas (plan) Executive Officer, Chief Quality Officer, Olympus Corporation (plan)
Number of shares of the Company held (Note 2) (Of which, the number of shares to be delivered under the stock compensation plan):		0 (0)

(Note 1) Brian Barry is scheduled to leave Medtronic plc effective on July 17, 2026 (U.S. time). As he remained with Medtronic plc as of the time of this release (3:30 p.m. on the same day, Japan time), his career summary reflects this position as “(present).”

(Note 2) “Number of shares of the Company held” indicates the number of shares held as of March 31, 2026. It also includes the number of shares each candidate holds through the Employees’ Shareholding Association of the Company, his/her own equity interest held through a company managing stock compensation of the Company as well as the number of shares to be delivered under the stock compensation plan.

4. New management team from August 1, 2026

The executive officers are stated by the alphabetical order of last name excluding the representative officer.

Bob White	Director, Representative Executive Officer, President and Chief Executive Officer
Brian Barry	Executive Officer, Chief Quality Officer
Simone Berger	Executive Officer, Chief Human Resources Officer
Keith Boettiger	Executive Officer, Gastrointestinal Solutions Division Head
John de Csepel	Executive Officer, Chief Medical Officer
Gabriela Kaynor	Executive Officer, Chief Strategy Officer
Seiji Kuramoto	Executive Officer, Surgical and Interventional Solutions Division Head
Syed Naveed	Executive Officer, Chief Technology Officer
Michael Parenti	Executive Officer, Chief Financial Officer
David Shan	Executive Officer, Chief Manufacturing and Supply Officer
Neil Boyden Tanner	Executive Officer, Global General Counsel